Narnatumab

Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.[2]

Narnatumab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetMST1R (aka RON)
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6454H10026N1754O2020S44
Molar mass145922.10 g·mol−1
 NY (what is this?)  (verify)

Narnatumab was developed by ImClone Systems.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.